Stock Analysis
ResMed Inc. (RMD) Stock Analysis
ResMed Inc. (RMD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
ResMed Inc. (RMD) currently has an AIQ Score of 54/100, indicating a neutral setup. Quality is the strongest factor at 80/100. Momentum is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RMD at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $218.27 |
| AIQ Score | 54/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $33.56B |
| P/E Ratio | 21.48 |
| Forward P/E | — |
| EPS | $2.65 |
| Revenue TTM | $1.46B |
| Dividend Yield | 0.01% |
| Beta | 0.75 |
| Volume | 912.32K |
| 52-week range | $180.27-$284.87 |
| RSI 14 | 29.72 |
| 50-Day SMA | $216.97 |
| 200-Day SMA | $227.85 |
| Analyst Price Target | $247.40 |
| Next Earnings | Oct 29, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
RMD
OverviewRMD Stock Analysis Summary
ResMed Inc. (RMD) currently has an AIQ Score of 54/100, indicating a neutral setup. Quality is the strongest factor at 80/100. Momentum is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RMD has AIQ Score of 54/100 with Quality base of 80/100 and fading Momentum at 29/100. Wait for component alignment before adding exposure.
Quality (80/100) leads while Momentum (29/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.60% stock move · RMD classified in Medical - Instruments & Supplies.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RMD Bullish or Bearish Right Now?
RMD currently has a neutral overall setup. Quality is the strongest factor at 80/100, while Momentum is weakest at 29/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 80/100.
- - Risk Resilience is supportive at 70/100.
- - Price is +0.60% above its 50-day SMA.
- - Analyst target implies +13.35% upside from the latest quote.
- - Value is the current constraint at 42/100.
- - Momentum is weak at 29/100.
- - Price is -4.21% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (30 vs 13).
Current Consensus
RMD's Technical Analysis Consensus is currently Sell, with 13 buy, 2 neutral, and 30 sell votes. RMD's 14-day RSI is 29.72, which places the stock in an oversold momentum range. RMD's beta is 0.75, indicating lower market sensitivity than the broad market.
What Changed in RMD?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the RMD Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RMD Decision Framework
Public evidence layers, setup checks, and risk context for ResMed Inc..
ResMed Inc. (RMD) Stock Analysis
ResMed Inc. has an AIQ Score of 54/100 in a Neutral regime. Quality is strongest at 80/100. Beta is 0.75, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RMD is in a Neutral AIQ regime with score 54/100. |
| Signal Conflict | The primary conflict is that quality leads at 80/100 while momentum lags at 29/100. |
| Factor Evidence | Momentum 29/100 · Value 42/100 · Quality 80/100 · Risk 70/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 80/100.
Momentum is 29/100 and RSI (14) is 29.7.
RMD is in a Neutral regime at 54/100.
Risk factor is 70/100 with beta 0.75 and annual volatility 28.46%.
Current conflict: quality leads at 80/100 while momentum lags at 29/100.
RMD Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RMD Fundamentals
RMD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RMD Technical Analysis
RMD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RMD Stock Catalysts
Track RMD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RMD Dividend Analysis
RMD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RMD Financial Data
RMD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RMD Risk Analysis
RMD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RMD Stock News
RMD stock news, market tone, recent headlines, and catalyst context.
RMD vs Medical Devices Peers
Current peer cohort: RMD · SOLV · STE · SYK · TFX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RMD Current stock | 54/100 | 42/100 | 29/100 | 70/100 | -0.75 | 28.46% | Current |
| SOLV Solventum | 61/100 | 67/100 | 50/100 | 56/100 | 0.71 | 29.78% | RMD vs SOLV |
| STE Steris | 46/100 | 48/100 | 15/100 | 72/100 | -0.6 | 25.56% | RMD vs STE |
| SYK Stryker | 43/100 | 42/100 | 8/100 | 55/100 | -1.1 | 29.49% | RMD vs SYK |
| TFX Teleflex | 47/100 | 62/100 | 29/100 | 64/100 | 0.12 | 40.39% | RMD vs TFX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts6 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RMD
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RMD
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RMD Stock FAQ
What is RMD stock price today?
ResMed Inc.'s current stock price is $218.27. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RMD bullish or bearish right now?
RMD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RMD's market cap?
RMD's market cap is $33.56B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RMD's current P/E ratio?
RMD's current P/E ratio is 21.48 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RMD's RSI?
RMD's 14-day RSI is 29.72 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RMD above its 50-day and 200-day moving averages?
RMD is 0.60% from its 50-day SMA and -4.21% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RMD's next earnings date?
RMD's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RMD pay a dividend?
RMD's dividend yield is 0.01% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.